It's our framework. The way we look at it is in accordance with the framework under the Competition Act.
We evaluated the Rogers-Shaw transaction. Our investigation determined that the transaction itself was going to substantially lessen competition. We brought an application to the tribunal in May 2022. There was no proposed acquisition by Videotron at the time we launched the application. That divestiture and all the agreements came to light in August, three months after we had filed their application. We evaluated it as a remedy. That is how the parties proposed it to us. We evaluated it as a remedy to address the anti-competitive effects of the Rogers-Shaw transaction. That is what we did.
Ultimately, the tribunal disagreed with us. The tribunal thought that we should not be evaluating it as a remedy, that it was a new transaction as of August 2022, so ultimately the tribunal disagreed with us.